Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease

Behavioural Brain Research

Volumn 229, Issue 1, 2012, Pages 208-215

  Castro, Adalberto A ^a   Ghisoni, Karina ^a   Latini, Alexandra ^a   Quevedo, João ^b   Tasca, Carla I ^a   Prediger, Rui D S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Intranasal; Lithium; Mood stabilizers; Non motor symptoms; Parkinson's disease; Valproate

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; LITHIUM; SEROTONIN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN PROTECTION; BRAIN REGION; CATECHOLAMINE DEPLETION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; FORCED SWIMMING TEST; INTERMETHOD COMPARISON; LOCOMOTION; MALE; MEMORY DISORDER; NONHUMAN; OLFACTORY BULB; OLFACTORY DISCRIMINATION; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SHORT TERM MEMORY; SMELLING DISORDER; SOCIAL INTERACTION; TASK PERFORMANCE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADMINISTRATION, INTRANASAL; AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; AVOIDANCE LEARNING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; LITHIUM; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OLFACTION DISORDERS; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); SEROTONIN; STATISTICS, NONPARAMETRIC; SWIMMING; VALPROIC ACID;

EID: 84856350760     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.01.016     Document Type: Article

References (80)

1. Allain H., Bentue-Ferrer D., Akwa Y. Disease-modifying drugs and Parkinson's disease. Prog Neurobiol 2008, 84:25-39.
2. Bosboom J.L., Stoffers D., Wolters E. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 2004, 111:1303-1315.
3. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318:121-134.
4. Carr W.J., Yee L., Gable D., Marasco E. Olfactory recognition of conspecifics by domestic Norway rats. J Comp Physiol Psychol 1976, 90:821-828.
5. Chaudhuri K.R., Healy D.G., Schapira A.H., National Institute for Clinical Excellence Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5:235-245.
6. Chen P.S., Peng G.S., Li G., Yang S., Wu X., Wang C.C., et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006, 11:1116-1125.
7. Chen R.W., Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999, 274:6039-6042.
8. Chiueh C.C., Markey S.P., Burns R.S., Johannessen J.N., Pert A., Kopin I.J. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur J Pharmacol 1984, 100:189-194.
9. Chuang D.M., Chen R.W., Chalecka-Franaszek E., Ren M., Hashimoto R., Senatorov V., et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002, 4:129-136.
10. Chuang D.M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?. Crit Rev Neurobiol 2004, 16:83-90.
11. Coopersmith R., Weihmuller F.B., Kirstein C.L., Marshall J.F., Leon M. Extracellular dopamine increase in neonatal olfactory bulb during odor preference training. Brain Res 1991, 564:149-153.
12. Dantzer R., Bluthe R.M., Koob G.F., Le Moal M. Modulation of social memory in male rats by neurohypophyseal peptides. Psychopharmacology 1987, 91:363-368.
13. Dash P.K., Orsi S.A., Zhang M., Grill R.J., Pati S., Zhao J., et al. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS ONE 2010, 5:e11383.
14. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
15. Dawson T.M., Dawson V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat Neurosci 2002, 5:1058-1061.
16. Dluzen D.E., Kefalas G. The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice. Brain Res 1996, 741:215-219.
17. Dluzen D.E., Kreutzberg J.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) disrupts social memory/recognition processes in the male mouse. Brain Res 1993, 609:98-102.
18. Dluzen D.E., Muraoka S., Landgraf R. Olfactory bulb norepinephrine depletion abolishes vasopressin and oxytocin preservation of social recognition responses in rats. Neurosci Lett 1998, 254:161-164.
19. Doty R.L., Deems D.A., Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988, 38:1237-1244.
20. Doty R.L., Fergusson-Segall M., Lucki I., Kreider M. Effects of intrabulbar injections of 6-hydroxydopamine on ethyl acetate odor detection in castrate and non-castrate male rats. Brain Res 1988, 444:95-103.
21. Doty R.L., Risser J.M. Influence of the D2 dopamine receptor agonist quinpirole on the odor detection performance of rat before and after spiperone administration. Psychopharmacology 1989, 98:310-315.
22. Dubois B., Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997, 244:2-8.
23. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006, 70:1876-1884.
24. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006, 31:326-332.
25. Gall C.M., Hendry S.H., Seroogy K.B., Jones E.G., Haycock J.W. Evidence of coexistence of GABA and dopamine in neurons of the rat olfactory bulb. J Comp Neurol 1987, 266:307-318.
26. Gerlach M., Foley P., Riederer P. The relevance of preclinical studies for the treatment of Parkinson's disease. J Neurol 2003, 250(Suppl. 1):I31-I34.
27. Ghasemi M., Sadeghipour H., Poorheidari G., Dehpour A.R. A role for nitrergic system in the antidepressant-like effects of chronic lithium treatment in the mouse forced swimming test. Behav Brain Res 2009, 200:76-82.
28. Halasz N., Shepherd G.M. Neurochemistry of the vertebrate olfactory bulb. Neuroscience 1983, 10:579-619.
29. Hashimoto R., Hough C., Nakazawa T., Yamamoto T., Chuang D.M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002, 80:589-597.
30. Hicks C.W., Pandya M.M., Itin I., Fernandez H.H. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism Relat Disord 2011, 17:379-381.
31. Houghoghi V., Rezayof A., Zyaian S., Zarrindast M.R. Intradorsal hippocampal microinjection of lithium reverses morphine-induced impairment of memory in mice: interactions with dopamine receptor mechanism(s). Behav Pharmacol 2009, 20:680-687.
32. Jornada L.K., Valvassori S.S., Steckert A.V., Moretti M., Mina F., Ferreira C.L., et al. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J Psychiatr Res 2011, 45:162-168.
33. Kalaria R.N., Mitchell M.J., Harik S.I. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Proc Natl Acad Sci USA 1987, 84:3521-3525.
34. Kidd S.K., Schneider J.S. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 2011, 194:189-194.
35. Leng Y., Chuang D.M. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006, 26:7502-7512.
36. Leng Y., Liang M.H., Ren M., Marinova Z., Leeds P., Chuang D.M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008, 28:2576-2588.
37. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003, 26:81-104.
38. Monti B., Gatta V., Piretti F., Raffaelli S.S., Virgili M., Contestabile A. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res 2010, 17:130-141.
39. Monti B., Polazzi E., Batti L., Crochemore C., Virgili M., Contestabile A. Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death. J Neurochem 2007, 103:518-530.
40. Moreira E.L., Rial D., Aguiar A.S., Figueiredo C.P., Siqueira J.M., DalBo S., et al. Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. J Neural Transm 2010, 117:1337-1351.
41. Nocjar C., Hammonds M.D., Shim S.S. Chronic lithium treatment magnifies learning in rats. Neuroscience 2007, 150:774-788.
42. Nonaka S., Chuang D.M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998, 9:2081-2084.
43. Nutt J., Williams A., Plotkin C., Eng N., Ziegler M., Calne D.B. Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations. Can J Neurol Sci 1979, 6:337-343.
44. Offen D., Beart P.M., Cheung N.S., Pascoe C.J., Hochman A., Gorodin S., et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA 1998, 95:5789-5794.
45. Owen A.M. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 2004, 10:525-537.
46. Pascual T., Gonzalez J.L. A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system. Brain Res 1995, 695:289-292.
47. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
48. Prediger R.D., Aguiar A.S., Matheus F.C., Walz R., Antoury L., Raisman-Vozari R., et al. Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease. Neurotox Res 2012, 21:90-116.
49. Prediger R.D., Aguiar A.S., Moreira E.L., Matheus F.C., Castro A.A., Walz R., et al. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease. Curr Pharm Des 2011, 17:489-507.
50. Prediger R.D., Aguiar A.S., Rojas-Mayorquin A.E., Figueiredo C.P., Matheus F.C., Ginestet L., et al. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Neurotox Res 2010, 17:114-129.
51. Prediger R.D., Batista L.C., Medeiros R., Pandolfo P., Florio J.C., Takahashi R.N. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 2006, 202:391-403.
52. Prediger R.D., Batista L.C., Miyoshi E., Takahashi R.N. Facilitation of short-term social memory by ethanol in rats is mediated by dopaminergic receptors. Behav Brain Res 2004, 153:149-157.
53. Prediger R.D., Batista L.C., Takahashi R.N. Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. Neurobiol Aging 2005, 26:957-964.
54. Prediger R.D., Da Cunha C., Takahashi R.N. Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpine-treated rats. Behav Pharmacol 2005, 16:209-218.
55. Prediger R.D., Rial D., Medeiros R., Figueiredo C.P., Doty R.L., Takahashi R.N. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease. Ann N Y Acad Sci 2009, 1170:629-636.
56. Price P.A., Parkes J.D., Marsden C.D. Sodium valproate in the treatment of levodopa-induced dyskinesia. J Neurol Neurosurg Psychiatry 1978, 41:702-706.
57. Qing H., He G., Ly P.T., Fox C.J., Staufenbiel M., Cai F., et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008, 205:2781-2789.
58. Redrobe J.P., Bourin M. The effect of lithium administration in animal models of depression: a short review. Fundam Clin Pharmacol 1999, 13:293-299.
59. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976, 38:277-301.
60. Sallaz M., Jourdan F. Apomorphine disrupts odour-induced patterns of glomerular activation in the olfactory bulb. Neuroreport 1992, 3:833-836.
61. Santiago R.M., Barbieiro J., Lima M.M., Dombrowski P.A., Andreatini R., Vital M.A. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1104-1114.
62. Sawyer T.F., Hengehold A.K., Perez W.A. Chemosensory and hormonal mediation of social memory in male rats. Behav Neurosci 1984, 98:908-913.
63. Schintu N., Frau L., Ibba M., Garau A., Carboni E., Carta A.R. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res 2009, 16:127-139.
64. Sgobio C., Ghiglieri V., Costa C., Bagetta V., Siliquini S., Barone I., et al. Hippocampal synaptic plasticity, memory, and epilepsy: effects of long-term valproic acid treatment. Biol Psychiatry 2010, 67:567-574.
65. Shim S.S., Hammonds M.D., Ganocy S.J., Calabrese J.R. Effects of sub-chronic lithium treatment on synaptic plasticity in the dentate gyrus of rat hippocampal slices. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:343-347.
66. Shipley M.T., Halloran F.J., de la Torre J. Surprisingly rich projection from locus coeruleus to the olfactory bulb in the rat. Brain Res 1985, 329:294-299.
67. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
68. Tandberg E., Larsen J.P., Aarsland D., Cummings J.L. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996, 53:175-179.
69. Tariot P.N., Loy R., Ryan J.M., Porsteinsson A., Ismail S. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 2002, 54:1567-1577.
70. Taylor T.N., Greene J.G., Miller G.W. Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res 2010, 211:1-10.
71. Tsaltas E., Kontis D., Boulougouris V., Papadimitriou G.N. Lithium and cognitive enhancement: leave it or take it. Psychopharmacology 2009, 202:457-476.
72. Tsaltas E., Kyriazi T., Poulopoulou C., Kontis D., Maillis A. Enhancing effects of lithium on memory are not by-products of learning or attentional deficits. Behav Brain Res 2007, 180:241-245.
73. Umka J., Mustafa S., ElBeltagy M., Thorpe A., Latif L., Bennett G., et al. Valproic acid reduces spatial working memory and cell proliferation in the hippocampus. Neuroscience 2010, 166:15-22.
74. Walz R., Roesler R., Quevedo J., Rockenbach I.C., Amaral O.B., Vianna M.R., et al. Dose-dependent impairment of inhibitory avoidance retention in rats by immediate post-training infusion of a mitogen-activated protein kinase kinase inhibitor into cortical structures. Behav Brain Res 1999, 105:219-223.
75. Weldon D.A., Travis M.L., Kennedy D.A. Posttraining D1 receptor blockade impairs odor conditioning in neonatal rats. Behav Neurosci 1991, 105:450-458.
76. Yang L., Matthews R.T., Schulz J.B., Klockgether T., Liao A.W., Martinou J.C., et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 1998, 18:8145-8152.
77. Youdim M.B., Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 2004, 46:1130-1140.
78. Zgaljardic D.J., Borod J.C., Foldi N.S., Mattis P. A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. Cogn Behav Neurol 2003, 16:193-210.
79. Zhang X., Heng X., Li T., Li L., Yang D., Du Y., et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis 2011, 24:739-749.
80. Zhu Z.F., Wang Q.G., Han B.J., William C.P. Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice. Brain Res Bull 2010, 83:272-277.